Display options
Cite
Carmalt ED, Cortez LM, Rosenblatt JE. Clinical experience with tobramycin in the treatment of infections due to gram-negative bacilli. Am J Med Sci. 1976;271(3):285-95doi: 10.1097/00000441-197605000-00004.
Carmalt, E. D., Cortez, L. M., & Rosenblatt, J. E. (1976). Clinical experience with tobramycin in the treatment of infections due to gram-negative bacilli. The American journal of the medical sciences, 271(3), 285-95. https://doi.org/10.1097/00000441-197605000-00004
Carmalt, E D, et al. "Clinical experience with tobramycin in the treatment of infections due to gram-negative bacilli." The American journal of the medical sciences vol. 271,3 (1976): 285-95. doi: https://doi.org/10.1097/00000441-197605000-00004
Carmalt ED, Cortez LM, Rosenblatt JE. Clinical experience with tobramycin in the treatment of infections due to gram-negative bacilli. Am J Med Sci. 1976 May-Jun;271(3):285-95. doi: 10.1097/00000441-197605000-00004. PMID: 820195.
Copy Download .nbib Format: NLM
Share it on

Am J Med Sci. 1976 May-Jun;271(3):285-95. doi: 10.1097/00000441-197605000-00004.

Clinical experience with tobramycin in the treatment of infections due to gram-negative bacilli.

The American journal of the medical sciences

E D Carmalt, L M Cortez, J E Rosenblatt

PMID: 820195 DOI: 10.1097/00000441-197605000-00004

Abstract

Tobramycin, a new aminocyclitol antimicrobial agent, was administered parenterally to 28 patients infected with gram-negative bacilli. The dosage was 1.5 mg/kg every 8 hours, except in patients with renal insufficiency in whom the dosage interval was 10 times the serum creatinine in hours. Serum levels after intramuscular administration were 3.9 +/- 1.6 mug/ml and 1.0 +/- 0.7 mug/ml at 2 and 8 hours, respectively. Serum levels after intravenous administration were 4.6 +/- 0.5 mug/ml, 2.3 +/- 0.6 mug/ml, and 0.6 +/- 0.8 mug/ml at 15 minutes, 1 hour, and 8 hours, respectively. Clinical isolates included 21 of Pseudomonas aeruginosa, 6 of Klebsiella pneumoniae, 2 of Serratia marcescens, and also isolates of E. coli, Proteus mirabilis, and Enterobacter. The minimum inhibitory concentrations (MICs) of tobramycin, gentamicin, sisomicin, and amikacin were determined for these organisms. Clinical results included 18 cures, 3 improvements, 2 indeterminates, and 6 failures. Minimal hepatic and renal toxicity was observed.

Similar articles

Substances

MeSH terms

Publication Types